EGFR and non-small cell lung carcinoma: Here we optimized administration of the erlotinib iPAI probes and extended TRIPODD to analyze therapeutic response in EGFRmut+ NSCLC xenografts as measured by changes in DTA and EGFR signaling pathway protein expression demonstrating the capability of TRIPODD to generate a mechanistic understanding of therapeutic response (Fig. 1).